B. Metzler seel. Sohn & Co. Holding AG Acquires New Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

B. Metzler seel. Sohn & Co. Holding AG bought a new position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) during the third quarter, according to the company in its most recent disclosure with the SEC. The firm bought 23,817 shares of the biopharmaceutical company’s stock, valued at approximately $1,323,000.

Other hedge funds also recently made changes to their positions in the company. nVerses Capital LLC bought a new position in Ultragenyx Pharmaceutical during the second quarter worth $33,000. UMB Bank n.a. lifted its position in shares of Ultragenyx Pharmaceutical by 58.1% in the 2nd quarter. UMB Bank n.a. now owns 958 shares of the biopharmaceutical company’s stock worth $39,000 after buying an additional 352 shares during the last quarter. Values First Advisors Inc. acquired a new position in shares of Ultragenyx Pharmaceutical in the 3rd quarter valued at about $56,000. Capital Performance Advisors LLP bought a new stake in shares of Ultragenyx Pharmaceutical during the 3rd quarter valued at about $107,000. Finally, Quest Partners LLC acquired a new stake in Ultragenyx Pharmaceutical during the third quarter worth about $119,000. Institutional investors and hedge funds own 97.67% of the company’s stock.

Insider Buying and Selling

In related news, CEO Emil D. Kakkis sold 20,000 shares of Ultragenyx Pharmaceutical stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $55.85, for a total value of $1,117,000.00. Following the transaction, the chief executive officer now owns 2,223,985 shares of the company’s stock, valued at approximately $124,209,562.25. This trade represents a 0.89 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Howard Horn sold 7,465 shares of the company’s stock in a transaction dated Thursday, October 10th. The shares were sold at an average price of $52.76, for a total transaction of $393,853.40. Following the sale, the chief financial officer now directly owns 92,301 shares of the company’s stock, valued at $4,869,800.76. This represents a 7.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 27,556 shares of company stock worth $1,515,967. Corporate insiders own 5.80% of the company’s stock.

Ultragenyx Pharmaceutical Price Performance

RARE opened at $47.24 on Friday. Ultragenyx Pharmaceutical Inc. has a 1-year low of $37.02 and a 1-year high of $60.37. The company has a market capitalization of $4.36 billion, a price-to-earnings ratio of -7.30 and a beta of 0.58. The business has a 50 day moving average price of $53.37 and a two-hundred day moving average price of $48.36.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) earnings per share for the quarter, beating the consensus estimate of ($1.45) by $0.05. Ultragenyx Pharmaceutical had a negative return on equity of 187.12% and a negative net margin of 106.93%. The business had revenue of $139.49 million during the quarter, compared to analysts’ expectations of $135.28 million. During the same quarter last year, the business posted ($2.23) earnings per share. The company’s quarterly revenue was up 42.3% on a year-over-year basis. Equities analysts expect that Ultragenyx Pharmaceutical Inc. will post -6.21 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have commented on RARE. Wells Fargo & Company lifted their target price on Ultragenyx Pharmaceutical from $72.00 to $75.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. Barclays reduced their price objective on Ultragenyx Pharmaceutical from $83.00 to $81.00 and set an “overweight” rating for the company in a research report on Monday, August 5th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $77.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, November 6th. TD Cowen boosted their price target on shares of Ultragenyx Pharmaceutical from $61.00 to $73.00 and gave the company a “buy” rating in a report on Monday, October 21st. Finally, Canaccord Genuity Group restated a “buy” rating and set a $121.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, November 12th. Two investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $87.46.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.